Vildagliptin Recruits Regulatory T Cells in Patients Undergoing Primary Percutaneous Coronary Intervention

References

• Adela R, Nethi SK, Bagul PK, et al. (2015). Hyperglycaemia enhances nitric oxideproduction in diabetes: a study from South Indian patients. PLoS ONE, 10, e0125270. doi: 10.1371/journal.pone.0125270 [ eCollection 201].
   PubMed Web of Science ®Google Scholar
• Al-Harbi NO, Imam F, Al-Harbi MM, et al. (2016). Dexamethasone attenuates LPS-induced acute lung injury through inhibition of NF-κB, COX-2, and pro-inflammatory mediators. Immunol Invest, 45, 349–369. doi: 10.3109/08820139.2016.1157814. Epub 2016 Apr 22.
   PubMed Web of Science ®Google Scholar
• Aroor A, McKarns S, Nistala R, et al. (2013). DPP-4 inhibitors as therapeutic modulators of immune cell function and associated cardiovascular and renal insulin resistance in obesity and diabetes. Cardiorenal Med, 3, 48–56. doi: 10.1159/000348756. Epub 2013 Mar 16.
   PubMed Web of Science ®Google Scholar
• Aso Y, Fukushima M, Sagara M, et al. (2015). Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes. Diabetes Res Clin Pract, 110, 250–256. doi: 10.1016/j.diabres.2015.10.012. Epub 2015 Oct 20.
   PubMed Web of Science ®Google Scholar
• Bar-Or D, Lau E, Winkler JV. (2000). A novel assay for cobalt albumin binding and its potential as a marker for myocardial ischemia – a preliminary report. J Emerg Med, 19, 311–315.
   PubMed Web of Science ®Google Scholar
• Buja LM. (2005). Myocardial ischemia and reperfusion injury. Cardiovasc Pathol, 14, 170–175.
   PubMed Web of Science ®Google Scholar
• Chen W, Jin W, Hardegen N, et al. (2003). Conversion of peripheral CD4+CD252 naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med, 198, 1875–1886.
   PubMed Web of Science ®Google Scholar
• Chinda K, Chattipakorn S, Chattipakorn N. (2012). Cardioprotective effects of incretin during ischaemia–reperfusion. Diab Vasc Dis Res, 9, 256–269. doi: 10.1177/1479164112440816.
   PubMed Web of Science ®Google Scholar
• Chinda K, Palee S, Surinkaew S, et al. (2013). Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia–reperfusion injury. Int J Cardiol, 167, 451–457. doi: 10.1016/j.ijcard.2012.01.011. Epub 2012 Jan 27.
   PubMed Web of Science ®Google Scholar
• Collinson PO, Gaze DC. (2008). Ischaemia-modified albumin: clinical utility and pitfalls in measurement. J Clin Pathol, 61, 1025–1028.
   PubMed Web of Science ®Google Scholar
• Dobaczewski M1, Chen W, Frangogiannis NG. (2011). Transforming growth factor (TGF)-β signaling in cardiac remodeling. J Mol Cell Cardiol, 51, 600–606. doi: 10.1016/j.yjmcc.2010.10.033. Epub 2010 Nov 6.
   PubMed Web of Science ®Google Scholar
• Eapen ZJ, Tang WH, Felker GM, et al. (2012). Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward. Circ Cardiovasc Qual Outcomes, 5: 594–600.
   PubMed Web of Science ®Google Scholar
• Fang J, Hu F, Ke D, et al. (2016). N,N-dimethylsphingosine attenuates myocardial ischemia–reperfusion injury by recruiting regulatory T cells through PI3K/Akt pathway in mice. Basic Res Cardiol, 111, 32–46. doi:10.1007/s00395-016-0548-3.
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Ménard C, Martin F, Zitvogel L. (2006). The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev, 214, 229–238.
   PubMed Web of Science ®Google Scholar
• Ikeuchi M, Tsutsui H, Shiomi T, et al. (2004). Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res, 64, 526–535.
   PubMed Web of Science ®Google Scholar
• Li K, Xu W, Guo Q, et al. (2009). Differential macrophage polarization in male and female BALB/c mice infected with coxsackievirus B3 defines susceptibility to viral myocarditis. Circ Res, 105, 353–364.
   PubMed Web of Science ®Google Scholar
• Meng X, Yang J, Dong M, et al. (2016). Regulatory T cells in cardiovascular diseases. Nat Rev Cardiol, 13, 167–179. doi: 10.1038/nrcardio.2015.169. Epub 2015 Nov 3.
   PubMed Web of Science ®Google Scholar
• Mor A, Planer D, Luboshits G, et al. (2007). Role of naturally occurring CD4+CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol, 27, 893–900.
   PubMed Web of Science ®Google Scholar
• Naohito I, Kaushik PP, Pascale HL, et al. (2001). Nitric oxide synthesis and oxidative stress in the renal cortex of rats with diabetes mellitus. J Am Soc Nephrol, 12, 1630–1639.
   PubMed Web of Science ®Google Scholar
• Ohkura N, Kitagawa Y, Sakaguchi S. (2013). Development and maintenance of regulatory T cells. Immunity, 38, 414–423. doi:10.1016/j.immuni.2013.03.002.
   PubMed Web of Science ®Google Scholar
• Puijvelde GH. (2007). Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis. Arterioscler Thromb Vasc Biol, 27, 2677–2683.
   PubMed Web of Science ®Google Scholar
• Ricciardelli I, Lindley KJ, Londei M, Quaratino S. (2008). Anti tumour necrosis-alpha therapy increases the number of FOXP3(+) regulatory T cells in children affected by Crohn’s disease. Immunology, 125, 178–183.
   PubMed Web of Science ®Google Scholar
• Richards H, Williams A, Jones E, et al. (2010). Novel role of regulatory T cells in limiting early neutrophil responses in skin. Immunology, 131, 583–592. doi: 10.1111/j.1365-2567.2010.03333.x. Epub 2010 Aug 17.
   PubMed Web of Science ®Google Scholar
• Ta NN, Schuyler CA, Li Y, et al. (2011). DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol, 58, 157–166.
   PubMed Web of Science ®Google Scholar
• Talwalkar SS, Bon Homme M, Miller JJ, Elin RJ. (2008). Ischemia modified albumin, a marker of acute ischemic events: a pilot study. Ann Clin Lab Sci, 38, 132–137.
   PubMed Web of Science ®Google Scholar
• Tang TT, Yuan J, Zhu ZF, et al. (2012). Regulatory T cells ameliorate cardiac remodeling after myocardial infarction. Basic Res Cardiol, 107, 232. doi:10.1007/s00395-011-0232-6.
   PubMed Web of Science ®Google Scholar
• Weirather J, Hofmann UD, Beyersdorf N, et al. (2014). Foxp3+ CD4+ T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiation. Circ Res, 115, 55–67.
   PubMed Web of Science ®Google Scholar
• Woo JS1, Kim W, Ha SJ, et al. (2013). Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler Thromb Vasc Biol, 33, 2252–2260. doi: 10.1161/ATVBAHA.113.301586. Epub 2013 Jul 18.
   PubMed Web of Science ®Google Scholar
• Xia N, Jiao J, Tang TT, et al. (2015). Activated regulatory T-cells attenuate myocardial ischaemia/reperfusion injury through a CD39-dependent mechanism. Clin Sci (Lond), 128, 679–693. doi:10.1042/CS20140672.
   PubMed Web of Science ®Google Scholar
• Zhang X, Fu Y, Xu X, et al. (2014). PERK pathway are involved in NO-induced apoptosis in endothelial cells cocultured with RPE under high glucose conditions. Nitric Oxide, 40C, 10–16.
   Google Scholar